RxDoctor Payments DataLook up a doctor →

Lynsay Brautnick, MD

Hematology & Oncology · Fayetteville, ARNPI 1548317340

Payments from drug & device makers

$6,746in general payments, 2019–2025

Across 453 payments — averaging $14.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$999
  • AstraZeneca$517
  • Novartis$408
  • Ipsen Biopharmaceuticals, Inc$334
  • GSK$298
  • Amgen$278
  • plus $4K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson(2 entities)52$999
AstraZeneca25$517
Novartis26$408
Ipsen Biopharmaceuticals, Inc34$334
GSK24$298
Amgen22$278
Sanofi15$270
Gilead(2 entities)20$269
Bristol Myers Squibb21$259
Regeneron Healthcare Solutions, Inc.15$230
Eisai Inc.14$204
Exelixis Inc.10$143
Astellas Pharma US Inc9$136
Takeda Pharmaceuticals U.S.A., Inc.8$129
E.r. Squibb & Sons, L.L.C.9$129
Jazz Pharmaceuticals Inc.9$123
Daiichi Sankyo Inc.7$114
Genentech USA, Inc.7$103
Foundation Medicine, Inc.4$101
Lilly USA, LLC7$93
Rigel Pharmaceuticals, Inc.6$83
Merck6$81
Incyte Corporation5$78
AVEO Pharmaceuticals, Inc.4$71
Seagen Inc.5$63
AbbVie4$58
Blueprint Medicines Corporation4$57
Puma Biotechnology, Inc.4$55
Tesaro, Inc.3$55
Blue Earth Diagnostics4$52
Genmab U.S., Inc.3$45
Sobi, Inc3$43
Dendreon Pharmaceuticals LLC3$43
Pfizer3$43
Taiho Oncology, Inc.3$41
Epizyme, Inc.3$41
Karyopharm Therapeutics Inc.3$41
Acceleron Pharma, Inc.3$39
EMD Serono, Inc.3$37
Boehringer Ingelheim2$35
Mirati Therapeutics, Inc.2$34
Beigene USA, Inc.2$29
Array Biopharma Inc2$29
Clovis Oncology, Inc.3$29
Servier Pharmaceuticals LLC2$26
Pharmaessentia USA Corporation2$26
Agios Pharmaceuticals, Inc.2$24
Sumitomo Pharma America, Inc.2$24
Heron Therapeutics, Inc.2$24
Kyowa Kirin, Inc.2$23
ADC Therapeutics America, Inc.2$23
Grifols USA, LLC1$21
Helsinn Therapeutics (U.S.), Inc.1$20
Deciphera Pharmaceuticals Inc.1$17
Bayer1$16
Caris MPI, Inc.1$15
Global Blood Therapeutics, Inc.1$15
Pharmacosmos Therapeutics Inc.1$15
Iovance Biotherapeutics, Inc.1$14
Beone Medicines USA, Inc.1$14

How this compares

$6,746 in reported general payments places this provider in the 45th percentile of 92 hematology & oncology providers in Arkansas.

See all hematology & oncology providers in Arkansas →

Medicare billing

Part B allowed, 2024
$4,673,531
Medicare patients
1,344
Services billed
216,284

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Fayetteville

See the full list for Arkansas →

Where these figures come from

Is this you, or does something look wrong? →